If you have been reading about ipamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
=== Non-tuberculous mycobacteria === Isoniazid may also be used off-label to treat nontuberculous mycobacterial pulmonary disease. Isoniazid was widely used in the treatment of Mycobacterium avium complex as part of a regimen including rifampicin and ethambutol. Evidence suggests that isoniazid prevents mycolic acid synthesis in M. avium complex as in M. tuberculosis and although this is not bactericidal to M. avium complex, it greatly potentiates the effect of rifampicin.
Hence, the majority of the carbon dioxide is not converted into carbonic acid, but remains as CO2 molecules, not affecting the pH. The relative concentrations of CO2, H2CO3, and the deprotonated forms HCO3– (bicarbonate) and CO32– (carbonate) depend on the pH. As shown in a Bjerrum plot, in neutral or slightly alkaline water (pH > 6.5), the bicarbonate form predominates (>50%) becoming the most prevalent (>95%) at the pH of seawater. In very alkaline water (pH > 10.4), the predominant (>50%) form is carbonate. The oceans, being mildly alkaline with typical pH = 8.2–8.5, contain about 120 mg of bicarbonate per liter. Being diprotic, carbonic acid has two acid dissociation constants, the first one for the dissociation into the bicarbonate (also called hydrogencarbonate) ion (HCO3–):
The Tandem t:slim X2 insulin pump, made by Tandem Diabetes, can be integrated with the Dexcom G6 or Dexcom G7 Continuous Glucose Monitoring Systems to automate glucose regulation. Using real-time glucose data from the CGM, the t:slim X2 uses an algorithm to adjust insulin delivery based on these readings, helping to prevent glucose highs and lows. This integration enables more flexible management of blood sugar levels throughout the day. The t:slim X2 uses two predictive technologies when connected to the Dexcom CGM: Control-IQ and Basal-IQ. Control-IQ is a hybrid closed-loop system that predicts glucose levels up to 30 minutes in advance using Dexcom CGM data. It adjusts basal insulin delivery by increasing, decreasing, or halting insulin delivery as needed to maintain glucose levels within a target range. Additionally, Control-IQ can automatically administer up to one correction bolus per hour if glucose levels are expected to rise. Basal-IQ also uses Dexcom G6 data to predict glucose trends but primarily focuses on preventing lows. It stops insulin delivery if glucose is expected to drop below 4.4 mmol/L (72 mg/dL) and resumes delivery once glucose levels rise. However, Basal-IQ does not administer correction boluses or adjust insulin for elevated glucose levels.
Sources: en.wikipedia.org
== History == The physical principles of ion traps were first explored by F. M. Penning, who observed that electrons released by the cathode of an ionization vacuum gauge follow a long cycloidal path to the anode in the presence of a sufficiently strong magnetic field. Later Wolfgang Paul developed a method to trap ions without magnetic fields that was based on his work with quadrupole mass spectrometers. Ion traps were used in television receivers prior to the introduction of aluminized CRT faces around 1958, to protect the phosphor screen from ions. The ion trap must be delicately adjusted for maximum brightness.
In 1968, a period of political liberalization took place in Czechoslovakia called the Prague Spring. An "Action Program" of reforms included increasing freedom of the press, freedom of speech and freedom of movement, along with an economic emphasis on consumer goods, the possibility of a multiparty government, limitations on the power of the secret police, and potential withdrawal from the Warsaw Pact. In answer to the Prague Spring, on 20 August 1968, the Soviet Army, together with most of their Warsaw Pact allies, invaded Czechoslovakia. The invasion was followed by a wave of emigration, including an estimated 70,000 Czechs and Slovaks initially fleeing, with the total eventually reaching 300,000. The invasion sparked intense protests from Yugoslavia, Romania, China, and from Western European countries.
=== Remotely controlled ovens === Embedded Web Technology (EWT) software—originally developed by NASA for use by astronauts operating experiments on the International Space Station—lets a user monitor and/or control a device remotely over the Internet. NASA supplied this technology and guidance to TMIO LLC, which developed remote control and monitoring of a new intelligent oven product named "Connect Io." With combined cooling and heating capabilities, Connect Io refrigerates food until a customized pre-programmable cooking cycle begins. The menu allows the user to simply enter the dinner time, and the oven automatically switches from refrigeration to the cooking cycle, so that the meal will be ready as the family arrives home for dinner.
Canadian National Capital Commission: The Gift of Tulips Archived 14 May 2012 at the Wayback Machine Bulb flower production » Tulip, International Flower Bulb Centre Tulip Picture Book, International Flower Bulb Centre
Sources: en.wikipedia.org
Coating defines the biocompatibility of the therapeutic agent and its ability to travel in the body. When the agent is not biocompatible, it will quickly be excreted from the body, and there will be magnetic accumulation or off-target therapeutic effects. The use of organic or inorganic coating molecules increases the half-life of the nanocarrier by delaying its clearance by the reticuloendothelial system (RES). This delay occurs because the coating overcomes the pH, hydrophobicity, and surface charge of the magnetic nanoparticles. Additionally, coating allows molecules to covalently bind to specific molecules, such as ligands, proteins, or antibodies, which provides binding specificity to target tissues. A common structure of coating includes the core-shell structure. In this structure, metal oxide cores are coated with biocompatible materials which allows for increased control and biocompatibility. The most common coatings used for optimum response involve the use of polysaccharides like dextran and polymers like polyethylene glycol. Furthermore, carbon coatings have proved to be biocompatible and have high capacity for absorption into cells. Even polyaniline with anti-cancer agent epirubicin can be used for tumor exploration of the brain. Polyethyleneimine has displayed high cellular accumulation and low toxicity. This coating was found to have poor pharmacokinetic properties when used alone, but with magnetic field induction, it was found to accumulate on tumors at clinically significant rates.
== Education == Both Ondetti brothers went to a vocational high school to study bookkeeping and accounting. At the age of 16, Miguel Ondetti worked a day job while conducting his studies at night. Ondetti stated, "But then, I was already interested in being scientist, I think probably from the year that I started high school" in his 1995 interview. His interest in chemistry stems from book borrowing from the public library. After graduating commercial high school, Ondetti experienced a major setback. The University of Buenos Aires denied admission because he did not receive a baccalaureate from an academic high school. Not discouraged, Ondetti audited his classes and received his baccalaureate in just two years. The University of Buenos Aires subsequently accepted him to their chemistry program. Ondetti supported himself during his university years by working as a bookkeeper, using his first high school degree. He managed to get an early shift at the Department of Energy. This allowed him to attend the required laboratory classes in the afternoon. Ondetti's experience with chemistry laboratory was unfamiliar to his previous knowledge in bookkeeping, but was not off-putting. Ondetti stated that his main interest was biology, "but one can't understand biology without chemistry". He used this for his motivation to studying chemistry. This philosophy has been strongly utilized in the past 30 years, long after Ondetti stated this fact. Ondetti studied chemistry in the early 1950s.
Food and Drug Administration (FDA) New Dietary Ingredient (NDI) notification, evaluated under Australia's Therapeutic Goods Administration (TGA) ingredient framework, and is protected by multiple international patent applications related to banana peel extract and its applications.
=== Osteoid in bone tumors === Osteosarcoma: The most common primary malignant bone tumor, osteosarcoma is characterized by malignant cells that produce osteoid. Osteosarcoma is a primary malignant tumour of the skeleton characterized by the direct formation of immature bone or osteoid tissue by the tumour cells. The production of osteoid by tumor cells is the histological hallmark distinguishing osteosarcoma from other bone tumors. The malignant osteoid produced appears as irregular, immature structures in close proximity to malignant cells with enlarged hyperchromatic nuclei and abnormal mitotic figures. Osteoid osteoma: A benign bone-forming tumor characterized by formation of osteoid tissue, typically causing localized bone pain that worsens at night.
== Procedure == Trichrome staining techniques employ two or more acid dyes. Normally acid dyes would stain the same basic proteins, but by applying them sequentially the staining pattern can be manipulated. A polyacid (such as phosphomolybdic acid or Phosphotungstic acid) is used to remove dye selectively. Polyacids are thought to behave as dyes with a high molecular weight: they displace easily removed dye from collagen. Usually a red dye in dilute acetic acid is applied first to overstain all components. Then a polyacid is applied to remove the red dye from collagen and some other components by displacement. A second acid dye (blue or green) in dilute acetic acid is applied which, in turn, displaces the polyacid, resulting in collagen stained in a contrasting colour to the initial dye used. If erythrocytes are to be stained, a small molecular weight yellow or orange dye is applied before staining with the red dye. It is usually applied from a saturated solution in 80% ethanol and often in conjunction with picric acid (itself a dye) and a polyacid. The methods exploit minor differences in tissue reaction to dyes, density, accessibility and so on. Trichrome stains in which dyes and a polyacid are applied sequentially are called multi-step trichromes. In "one-step" methods, all the dyes—with or without a polyacid—are combined in a single solution. One of the oldest single-step approaches to trichrome staining is van Gieson's method, which stains muscle and cytoplasm yellow, and collagen red. Another is the Gömöri trichrome stain, which closely mimics Masson's trichrome.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.